Investor notices continue to cover two unrelated securities matters. On Aug. 28, 2026, Bleichmar Fonti & Auld LLP announced that a securities fraud class action has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain senior executives in the U.S. District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385, with a Sept. 28, 2026 lead-plaintiff deadline. The complaint alleges false statements about Deramiocel clinical data and undisclosed pre-specified statistical analysis plan changes tied to the Biologics License Application, following a July 2025 Complete Response Letter, July 2026 FDA briefing documents, a non-binding advisory panel vote against efficacy, and multi-day share declines including a 64.5% drop. Separately, class actions against Aardvark Therapeutics, Inc. (NASDAQ: AARD) allege misstatements about ARD-101 safety and prospects for IPO-traceable purchasers and investors from Feb. 13, 2025 through May 14, 2026, with an Oct. 13, 2026 lead-plaintiff deadline. Hagens Berman, Bragar Eagel & Squire, Kaplan Fox, Rosen Law Firm, Pomerantz and BFA have issued related outreach on the distinct matters.